AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Boeing Working With Union, FAA to Review Employee Safety Reports
Bloomberg Businessweek
Weight Loss Drugs and Investment in Healthcare Sector
10min Snip
00:00
Summary
Transcript
Episode notes
The chapter explores the impact of weight loss drugs from the GLP1 class on kidney disease, diabetes, and obesity, featuring Novo Nordus and Lilly's developments. It discusses the potential health benefits beyond weight loss, emphasizing the role of medication as part of a holistic approach to weight management. The narrative also delves into the challenges of maintaining weight loss post-medication and Eli Lilly's significant investment in expanding manufacturing capabilities for weight loss drugs.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode